This is a part of a longer interview which you can watch in parts or listen in one go though it is posted on youtube as audio only for the latter.
Let’s say we find a way to reverse aging. How far could we wind things back and when should we do it?
David Sinclair and Adam Spencer tackling the thorny questions around aging, including how far could we turn back the biological clock, how would we do it, and when in our lifetime should we hit the reset button.
This clip is a recording from our Outside The Box series — an event where David examined how our understanding of aging as a disease is developing, and describes some of the simple methods anyone can use to live a healthier life for longer.
The event was hosted by Australian science communicator and radio personality, Adam Spencer.
ABOUT THINK INC. Think Inc. is a community of individuals on a mission to expose the true face of modern society. Armed with ideas, we defy the stale conventions of learning by shifting the world’s attention to global ideas, while opening minds.
We’re not on the fringe. We are trendsetters with the power to shift perceptions and reshape the face of the mainstream.
Telomerase is a ribonucleoprotein enzyme, which maintains genome integrity in eukaryotes and ensures continuous cellular proliferation. Telomerase holoenzyme from the thermotolerant yeast Hansenula polymorpha, in addition to the catalytic subunit (TERT) and telomerase RNA (TER), contains accessory proteins Est1 and Est3, which are essential for in vivo telomerase function. Here we report the high-resolution structure of Est3 from Hansenula polymorpha (HpEst3) in solution, as well as the characterization of its functional relationships with other components of telomerase. The overall structure of HpEst3 is similar to that of Est3 from Saccharomyces cerevisiae and human TPP1. We have shown that telomerase activity in H. polymorpha relies on both Est3 and Est1 proteins in a functionally symmetrical manner. The absence of either Est3 or Est1 prevents formation of a stable ribonucleoprotein complex, weakens binding of a second protein to TER, and decreases the amount of cellular TERT, presumably due to the destabilization of telomerase RNP. NMR probing has shown no direct in vitro interactions of free Est3 either with the N-terminal domain of TERT or with DNA or RNA fragments mimicking the probable telomerase environment. Our findings corroborate the idea that telomerase possesses the evolutionarily variable functionality within the conservative structural context.
“Eat your vitamins” might be replaced with “ingest your ceramic nano-particles” in the future as space research is giving more weight to the idea that nanoscopic particles could help protect cells from common causes of damage.
Oxidative stress occurs in our bodies when cells lose the natural balance of electrons in the molecules that we are made of. This is a common and constant occurrence that is part of our metabolism but also plays a role in the aging process and several pathological conditions, such as heart failure, muscle atrophy and Parkinson’s disease.
The best advice for keeping your body in balance and avoiding oxidative stress is still to have a healthy diet and eat enough vitamins, but nanoparticles are showing promising results in keeping cells in shape.
Melittin (MEL), a major peptide component of bee venom, is an attractive candidate for cancer therapy. This agent has shown a variety of anti-cancer effects in preclinical cell culture and animal model systems. Despite a convincing efficacy data against variety of cancers, its applicability to humans has met with challenges due to several issues including its non-specific cytotoxicity, degradation and hemolytic activity. Several optimization approaches including utilization of nanoparticle based delivery of MEL have been utilized to circumvent the issues. Here, we summarize the current understanding of the anticancer effects of bee venom and MEL on different kinds of cancers. Further, we also present the available information for the possible mechanism of action of bee venom and/or MEL.
Keywords: Bee venom, Melittin, Melittin conjugates, Cancer management, Anti-cancer effects.
Cancer is one of the major ailment effecting humankind and remains as one of the leading causes of mortality worldwide. The current available data suggests that over 10 million new patients are diagnosed with the disease every year and over 6 million deaths are associated with it representing roughly 12% of worldwide deaths. Fifteen million new cancer cases are anticipated to be diagnosed in the year 2020 [1] which will potentially increase to over 20 million by 2025 [2] and more in years to come. It is also anticipated that the growth and aging of the population may increase the new cancer cases to 21.7 million with about 13 million cancer deaths by the year 2030 [3].
The Buck Institute for Research on Aging scientists behind the research found that female mice that were fed enough AKG to maintain a younger mouse’s blood levels of the compound lived eight to 20 percent longer than the control group, according to research published Tuesday in the journal Cell Metabolism. On top of that, male and female mice who ate AKG had better fur color, stronger grips, and improved gait compared to others.
There’s a long and bumpy road between a successful mouse experiment and any sort of clinical applications for humans, but scientists are encouraged because AKG is already considered safe for humans to take.
“The big thing about this is that its safety profile is so good,” Holly Brown-Borg, a University of North Carolina aging researcher who didn’t work on the study told Science Magazine. “It has potential and should be explored further, for sure.”
Cellular Aquaculture — Feed The World and Save the Oceans — Lou Cooperhouse, President & CEO, of BlueNalu, joins me on ideaXme (https://radioideaxme.com/) to discuss his company’s technologies to provide the world with healthy and safe cell-based seafood products, and support the sustainability and diversity of our oceans — #Ideaxme #StemCells #Aquaculture #Oceans #Fish #Sushi #Poke #Ceviche #SustainableDevelopment #Agriculture #Health #Wellness #RegenerativeMedicine #Biotech #Longevity #Aging #IraPastor #Bioquark #Regenerage ideaXme BlueNalu Rutgers University Rich Products Sumitomo Chemical: Group Companies of the Americas KBW Investments.
Ira Pastor, ideaXme life sciences ambassador and founder of Bioquark, interviews Lou Cooperhouse, President and CEO of BlueNalu.
Ira Pastor comments:
Global demand for seafood is at an all time high, as consumers are increasingly choosing to eat an extraordinary variety of seafood products that exist worldwide. Unfortunately, our global supply for seafood cannot keep pace with this demand, as populations of marine species have halved since 1970. This is due to overfishing, illegal fishing, rising ocean temperatures, acidification, the effects of trawling, and a number of other environmental, social, and political challenges.
At the same time, consumers are looking for more from their food choices. Consumers are increasingly concerned about animal welfare and the conditions in which fish are farmed and caught. In addition, they are increasingly concerned about their own personal welfare, as seafood can be a source of mercury, toxins and poisons, pathogens, viruses, and parasites, micro-particles of plastics due to plastic pollution in our ocean, and a variety of other environmental pollutants.
Using biotechnology to create a sustainable cell based seafood food resource.
Cellular agriculture (or aquaculture per our theme today) focuses on the production of products from cell cultures using a combination of biotechnology, tissue engineering, molecular biology, and synthetic biology to create and design new methods of producing proteins, fats, and tissues that would otherwise come from traditional agriculture or aquaculture.
Lou Cooperhouse, is President and CEO of BlueNalu, a company whose mission is to be the global leader in cellular aquaculture, providing consumers with great tasting, healthy, safe and trusted cell-based seafood products that support the sustainability and diversity of our ocean.
Deploying “AI for Good” In The Life Sciences — Tom Lawry, National Director for Artificial Intelligence, Health & Life Sciences, Microsoft, joins me on ideaXme to discuss how they are deploying artificial intelligence “at scale”, across the major organizations responsible for delivery quality, next generation healthcare to millions of patients and customers — #Ideaxme #Microsoft #ArtificialIntelligence #MachineLearning #DeepLearning #Health #Healthcare #Wellness #Medicine #Pharmacy #Hospitals #Nursing #Insurance #Diagnostics #Data #Moonshots #Biotechnology #Longevity #LifeExtension #Aging #IraPastor #Bioquark #Regenerage
Ira Pastor, ideaXme life sciences ambassador, interviews Tom Lawry, National Director for Artificial Intelligence — Health & Life Sciences at Microsoft.
Ira Pastor Comments:
A set of tools that we have been hearing quite a bit about (and discussed a bit on the show) in recent years is the triad of artificial intelligence, machine learning, and deep learning and their respective applications (primarily in the drug discovery and development processes), in terms how university labs and startups are using some of these tools to better guide the rational drug design process, or more appropriately select patients for a clinical trial, per the field of personalized medicine.
Today we are going to go to the far end of the spectrum, to a view of the potential of these tools at “scale”, when they need to be deployed across the mega enterprises responsible for delivery quality, next generation healthcare to millions of customers.
Tom Lawry:
Tom Lawry is National Director for Artificial Intelligence — Health & Life Sciences at Microsoft. In this role he serves as a strategic advisor to provider, payer and life science organizations across the Americas, creating enterprise-wide AI initiatives designed to transform healthcare at scale.
He focuses on technological, process and cultural redesign leading to the creation of Intelligent Health Systems that better empower patients, consumers and clinicians.
Worldwide, 800,000 people die annually due to suicide (1 every 40 seconds) — There are more than twice as many suicides as homicides — Suicide is now the 10th leading cause of death in the US, and the 2nd leading cause of death among individuals between ages of 10 and 34 — Dr. Christine Moutier, M.D., Chief Medical Officer, American Foundation for Suicide Prevention, joins me on ideaXme to discuss her organization’s work in suicide prevention science and impacting these disturbing trends — #Ideaxme #Suicide #Depression #MentalHealth #Psychiatry #Anxiety #Stress #Trauma #Coronavirus #Burnout #WellBeing #Resilience #Health #Wellness #Longevity #Aging #IraPastor #Bioquark #Regenerage National Institute of Mental Health National Academy of Medicine.
Ira Pastor, ideaXme life sciences ambassador and founder of Bioquark, interviews Dr. Christine Moutier, MD, Chief Medical Officer, at the American Foundation for Suicide Prevention (AFSP).
Ira Pastor comments:
According to the World Health Organization (WHO), close to 800,000 people die due to suicide every year, which is one person every 40 seconds. Suicide is a global phenomenon and occurs throughout the lifespan, and there are indications that for each adult who died by suicide, there may have been more than 20 others attempting suicide.
According to the U.S. Centers for Disease Control and Prevention (CDC) “Leading Causes of Death Report”, in 2017 suicide was the tenth leading cause of death overall in the United States, claiming the lives of over 47,000 people; Suicide was the second leading cause of death among individuals between the ages of 10 and 34, and the fourth leading cause of death among individuals between the ages of 35 and 54. There were more than twice as many suicides in the United States as there were homicides.
Aiding Suicide Prevention Through Psychiatry.
Dr. Christine Moutier, MD is the Chief Medical Officer at the American Foundation for Suicide Prevention. Dr. Moutier earned her medical degree and training in psychiatry at the University of California, San Diego, and has been a practicing psychiatrist, professor and dean in the UCSD School of Medicine, medical director of the Inpatient Psychiatric Unit at the VA Medical Center in La Jolla, and has been clinically active with diverse patient populations, such as veterans, Asian refugee populations, as well as physicians and leaders with mental health conditions. She also served as co-investigator for the Sequenced Treatment Alternatives to Relieve Depression study (STAR*D), a large National Institute of Mental Health (NIMH) trial on the treatment of refractory depression.
Dr. Christine Moutier’s Career in Psychiatry and Mental Resilience.
Actually, the predominant language of the website is English, but even me being bilingual, I felt more comfortable delivering the narrative in my native language.
In the video, I give a thorough overview of the content and organization of my website Transhumanplus.com. It has a huge amount of information, growing constantly, on the transhumanist movement, emerging technologies in general, and very specially, on the longevity, rejuvenation and life extension field.
The idea is to provide a 20 minute guide to visitors, so you can have a good understanding and take the most out of it when surfing the web.
If you enjoy the video or are interested in these matters, I invite you to contact me through any of the following social media channels:
Ira Pastor ideaXme life sciences ambassador interviews Shelley Lyford, President and Chief Executive Officer of West Health, the Gary and Mary West Foundation, and the West Health Institute.
Ira comments:
According to the World Health Organization (WHO), the world is on the brink of a demographic milestone. Since the beginning of recorded history, young children have outnumbered their elders. In about 5 years’ time, the number of people aged 65 or older will outnumber children under age 5. Driven by falling fertility rates and remarkable increases in life expectancy, population aging will continue, and even accelerate. The number of people aged 65 or older is projected to grow from an estimated 524 million in 2010 to nearly 1.5 billion in 2050, with most of the increase in developing countries.
Key questions arise:
- Will population aging be accompanied by a longer period of good health, a sustained sense of well-being, and extended periods of social engagement and productivity, or will it be associated with more illness, disability, and dependency?
- How will aging affect health care and social costs?
- Can we act to establish a physical and social infrastructure that might foster better health and wellbeing in older age?
